SUSAN GILL: Open Payments
NPI 1225280464 · NAPLES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,459 in 194 payments from 27 companies in 2025. Trend: 2023 $4,321 · 2024 $3,142 · 2025 $4,459
Food & beverage: $4,294Education: $164
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 30 | $720 |
| Regeneron Healthcare Solutions, Inc. | 17 | $557 |
| GlaxoSmithKline, LLC. | 26 | $461 |
| GENZYME CORPORATION | 9 | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $282 |
| Insmed, Inc. | 16 | $231 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $195 |
| Verona Pharma, Inc. | 8 | $188 |
| Actelion Pharmaceuticals US, Inc. | 13 | $170 |
| Lilly USA, LLC | 3 | $149 |
Products named: DUPIXENT, NUCALA, AIRSUPRA, Arikayce, FASENRA, CUVITRU, Ohtuvayre, TRELEGY ELLIPTA.
Industry payments across FL — which companies pay providers there.
